Search results
SK Channels as a New AAD Target
Author(s):
Arnela Saljic
,
Jordi Heijman
,
Dobromir Dobrev
Added:
1 year ago
Review Article
Author(s):
Raúl Ludeña
,
Raúl Ptaszynski Lanza
,
Ana Las Hayas
,
et al
Added:
1 week ago
Development of Small-molecule SERCA Stimulators
Author(s):
Antonio Zaza
,
Marcella Rocchetti
Added:
9 months ago
Review Article
Conduction System Pacing: A Fresh Look
Author(s):
Óscar Cano, Marek Jastrzębski, Pugazhendhi Vijayaraman
Start date:
Nov 13, 2024
Broadcast
Author(s):
Larry Chinitz
Added:
1 year ago
HRS 24 - Dr Larry Chinitz (NYU School of Medicine, US) joins us to discuss the findings of the prospective, multicenter BIO-CONDUCT study, which investigated the safety and efficacy of the BIOTRONIK Solia S pacing lead implanted in the left bundle branch area (LBB) (NCT05251363, Biotronik Inc.). 186 patients with atrioventricular block, bradycardia, left bundle-branch block or cardiomyopathies…
View more
Author(s):
Laurent Fiorina
Added:
2 years ago
EHRA 24 - In this short interview, we are joined by Dr Laurent Fiorina (Cardiovascular Institute Paris-Sud (ICPS), FR) joins us to discuss the findings from a clinical investigation into diagnosing conduction tissue disease using an AI-enabled single-lead coronary ECG device.This observational, prospective clinical trial aims to investigate the performance of an artificial intelligence algorithm…
View more
Author(s):
Rodrigo Bagur, Angela McInerney, Rolf Kreutz ,et al
Start date:
Apr 23, 2025
This webinar brings together leading experts Dr Rodrigo Bagur, Dr Angela McInerney, Dr Rolf Kreutz, Dr Sohail Khan, Dr Sophia Khattak, Dr Jonathan Hinton and Dr Peter O’Kane to explore the challenges and solutions in managing calcified coronary artery disease. The session will provide a detailed examination of coronary calcification from pathological and clinical perspectives, including…
View more
Author(s):
Steven E Nissen
Added:
1 year ago
ACC 2025 - 540-day follow up of lepodisiran in patients with elevated lipoprotein(a) (Lp(A)) shows the extended duration of action of lepodisiran will allow infrequent dosing in the ongoing cardiovascular outcome trial.Dr Steven Nissen (Cleveland Clinic, Cleveland, US) joins us onsite at ACC to discuss the ALPACA phase 2 trial (NCT05565742), investigating the safety and efficacy of lepodisiran,…
View more
Author(s):
Manuel Sánchez Suárez
,
Alberto Alen Andrés
,
Andrés Álvarez
,
et al
Added:
1 week ago
Author(s):
Alberto Alen Andrés
,
María Salgado
,
Maria Fernández García
,
et al
Added:
1 week ago